The EPS beat is a non-event for a pre-revenue biotech with flat net loss and minimal cash. Watch for the first patient dosing in the DFU trial (Q2 2026) and any further capital raises — the $4M total cash post-offering provides limited runway.
Price Chart
Executive Summary
FibroBiologics reported Q1 2026 EPS of -$0.60, a 55.7% beat vs consensus of -$1.35, but net loss was flat YoY at $5.0M. Cash burn continues with only $1.5M in cash at quarter end, partially offset by a subsequent $2.5M direct offering. The beat is largely noise given the pre-revenue stage and minimal cash runway.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.60 vs consensus -$1.35 (55.7% beat)
- Net loss $5.0M flat YoY
- Cash and cash equivalents $1.5M at March 31, 2026
- Raised $2.5M net in registered direct offering subsequent to quarter end
- R&D expenses $3.0M vs $1.8M YoY, driven by CRO costs for clinical trial prep
- Phase 1/2 DFU trial CYWC628: first patient dosing expected Q2 2026, interim results Q3 2026
- Regained compliance with all Nasdaq listing requirements
- 270+ patents issued/pending
Financial Impact
EPS beat of $0.75 vs consensus; cash position $1.5M with $2.5M subsequent raise — runway likely <6 months without additional capital
Risk Factors
- Cash runway likely <6 months — high risk of dilutive financing
- Pre-revenue stage with no approved products
- Clinical trial execution risk for CYWC628 DFU trial
- Nasdaq compliance regained but fragile given low market cap ($7M)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285584 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 8, 2026 17d ago | 8-K | $1.13 $0.9710 | ▲ +14.07% | ▲ +12.10% | $0.9221 (+18.40%) |
Sep 15, 2026 5w ago | 8-K | $1.44 $1.43 | ▼ −0.69% | ▼ −1.51% | $0.9221 (−35.97%) |
Aug 24, 2026 9w ago | 8-K | $1.35 $1.72 | ▲ +27.41% | ▲ +26.94% | $0.9221 (−31.70%) |
Jul 31, 2026 12w ago | Press Release | $0.7910 $0.9800 | ▲ +23.89% | ▲ +21.87% | $0.9221 (+16.57%) |
Jul 17, 2026 14w ago | EFFECT | $0.8349 $0.7355 | ▲ +11.91% | ▲ +11.22% | $0.9221 (−10.44%) |
Jul 9, 2026 15w ago | 8-K | $0.8610 $0.8398 | ▼ −2.46% | ▼ −2.33% | $0.9221 (+7.10%) |
Jun 29, 2026 16w ago | 8-K | $0.9477 $0.8687 | ▲ +8.34% | ▲ +8.94% | $0.9221 (+2.70%) |
May 11, 2026 24w ago | Press Release | $0.9900 $1.09 | ▲ +10.10% | ▲ +10.19% | $0.9221 (−6.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers